AR106475A1 - Derivados de piridina o de pirimidina - Google Patents
Derivados de piridina o de pirimidinaInfo
- Publication number
- AR106475A1 AR106475A1 ARP160103260A ARP160103260A AR106475A1 AR 106475 A1 AR106475 A1 AR 106475A1 AR P160103260 A ARP160103260 A AR P160103260A AR P160103260 A ARP160103260 A AR P160103260A AR 106475 A1 AR106475 A1 AR 106475A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- cyclopropyl
- piridine
- ethyl
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) en la que: R¹’ es metilo; R¹ es metilo, etilo, CF₃, CH₂OH, ciclopropilo o ciano, o R¹’ y R¹ juntos pueden formar un anillo 1,1-dioxo-tetrahidro-tiofen-3-ilo; R² es hidrógeno, metilo, etilo, isopropilo, tert-butilo, ciclopropilo, ciclopropilmetilo o hidroximetilo; R³ es Cl, F, CF₃, metilo, metoxi o ciclopropilo; R⁴ es hidrógeno, metilo, F o Cl; X es N o CH; Y es N o CH; con la condición de que X e Y no sean CH al mismo tiempo; o una sal farmacéuticamente aceptable o una sal de adición de ácido, una mezcla racémica o sus enantiómeros correspondientes y/o isómeros ópticos y/o estereoisómeros.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15191887 | 2015-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR106475A1 true AR106475A1 (es) | 2018-01-17 |
Family
ID=54360941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160103260A AR106475A1 (es) | 2015-10-28 | 2016-10-26 | Derivados de piridina o de pirimidina |
Country Status (8)
Country | Link |
---|---|
US (1) | US10155741B2 (es) |
EP (1) | EP3368522B1 (es) |
JP (1) | JP6849668B2 (es) |
CN (1) | CN107922381B (es) |
AR (1) | AR106475A1 (es) |
HK (1) | HK1247192A1 (es) |
TW (1) | TW201718539A (es) |
WO (1) | WO2017072083A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6518789B2 (ja) | 2015-04-23 | 2019-05-22 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 精神障害の処置において使用するためのテトラゾール誘導体 |
EP3359537B1 (en) | 2015-10-06 | 2020-03-25 | H. Hoffnabb-La Roche Ag | Triazole derivatives |
WO2017133990A1 (en) | 2016-02-02 | 2017-08-10 | F. Hoffmann-La Roche Ag | Pyrazol-pyridine derivatives as eaat3 inhibitors |
EP3464246B1 (en) | 2016-05-27 | 2020-07-08 | H. Hoffnabb-La Roche Ag | Pyrazol compounds as eaat3 inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010003156A (es) * | 2007-10-04 | 2010-04-01 | Hoffmann La Roche | Derivados de aril amida substituida con tetrazol y usos de los mismos. |
US8598209B2 (en) * | 2008-10-31 | 2013-12-03 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
JP6518789B2 (ja) * | 2015-04-23 | 2019-05-22 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 精神障害の処置において使用するためのテトラゾール誘導体 |
EP3334727B1 (en) * | 2015-08-12 | 2019-05-15 | H. Hoffnabb-La Roche Ag | Pyridine and pyrimidine derivatives |
-
2016
- 2016-10-25 EP EP16793783.8A patent/EP3368522B1/en active Active
- 2016-10-25 WO PCT/EP2016/075590 patent/WO2017072083A1/en active Application Filing
- 2016-10-25 JP JP2018513843A patent/JP6849668B2/ja active Active
- 2016-10-25 CN CN201680050380.7A patent/CN107922381B/zh not_active Expired - Fee Related
- 2016-10-26 AR ARP160103260A patent/AR106475A1/es unknown
- 2016-10-27 TW TW105134681A patent/TW201718539A/zh unknown
-
2018
- 2018-04-17 US US15/954,964 patent/US10155741B2/en not_active Expired - Fee Related
- 2018-05-21 HK HK18106576.9A patent/HK1247192A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2017072083A1 (en) | 2017-05-04 |
CN107922381B (zh) | 2020-10-13 |
JP6849668B2 (ja) | 2021-03-24 |
EP3368522A1 (en) | 2018-09-05 |
JP2018535926A (ja) | 2018-12-06 |
CN107922381A (zh) | 2018-04-17 |
TW201718539A (zh) | 2017-06-01 |
HK1247192A1 (zh) | 2018-09-21 |
EP3368522B1 (en) | 2021-08-04 |
US10155741B2 (en) | 2018-12-18 |
US20180258066A1 (en) | 2018-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022000666A1 (es) | Compuesto de piridona fusionada y método de preparación del mismo y uso del mismo | |
AR105238A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
AR114631A1 (es) | Métodos e intermedios para preparar compuestos de piridina | |
CO2018004124A2 (es) | Compuestos heterocíclicos | |
UY38057A (es) | Inhibidores de sarcómero cardíaco | |
CU20200051A7 (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 | |
AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
AR106475A1 (es) | Derivados de piridina o de pirimidina | |
AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
AR104331A1 (es) | Derivados de tetrazol | |
PE20180600A1 (es) | Inhibidores de metalo-beta-lactamasa | |
AR095011A1 (es) | Compuestos de antranilamida, sus mezclas y usos como plaguicidas | |
AR102227A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
AR105662A1 (es) | Derivados de piridina y de pirimidina como inhibidores del eaat3 | |
CL2022001529A1 (es) | Nuevos derivados de metilquinazolinona | |
AR111806A1 (es) | Derivados de indol n-sustituidos | |
AR103412A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
NI202000058A (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
AR104528A1 (es) | Compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
AR101359A1 (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo | |
CO2022008171A2 (es) | Derivado tricíclico de dihidroimidazopirimidona, método de preparación del mismo, composición farmacéutica y uso del mismo | |
CY1121147T1 (el) | Νεες συντηγμενες ενωσεις ιμιδαζοβενζοθειαζολιου | |
CL2020002588A1 (es) | Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional de solicitud n° 03258-2016) | |
AR106185A1 (es) | Compuestos macrocíclicos de sulfondiimina | |
AR104863A1 (es) | Derivados imidazol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |